Among patients with diabetes and CKD, SBP <130 mmHg and DBP <80 mmHg were associated with reduced risk of CVD. #AHAJournals @HHLeeMD @hokyoulee https://t.co/dkMCAj5Jkc

Most Updated Global Burden of Cardiovascular Disease now out in @JACCJournals 80% (!) of CV disease burden is attributable to modifiable RFs Top modifiable risks in 2023: ⚠️ High systolic BP ⚠️ Dietary risks ⚠️ High LDL cholesterol ⚠️ Air pollution 🔗 https://t.co/EIvzZMQQPC

LATE Lunch Bites @SmithBIDMC Where our postdoctoral fellows & medical trainees get a front-row seat to wisdom from Nobel laureate @metrics52 Econometrics + science + life lessons = the best lunch in town

A new report in #JACC, published to coincide with a #UNGA80 event, highlights the urgent need to prioritize heart health. #CVD causes 1 in 3 deaths worldwide, driven by population growth, aging, obesity & diabetes. Get the details: https://t.co/O8Hi3rvW38 #GBDStudy @IHME_UW

This is an extraordinary report from @IHME_UW and published in @JACCJournals; it demonstrates that cardiovascular disease is a global scourge. And we are failing to leverage what we know to save lives. https://t.co/fJuiRnJjGn

CMS (@CMSGov) will soon be rolling out the WISeR model - the first major expansion of prior authorization in FFS Medicare. In @NEJM, we highlight concerns about misaligned incentives, potential harm to patients, and added strain on health systems. Link: https://t.co/slwyYFi6Kk

Racial disparities persist in the use of adjunctive PCI technology🫀 Mentored by the exceptional @EricSecemskyMD, guided by the wonderful @rwyeh, and with unwavering support from @JMKimMD. Proud to present one of my @SarnoffCardio supported projects. https://t.co/MTZ4t5Nnxo

I think I have a positive bias toward the PARTHENOPE trial, not only because I was part of the Steering Committee and deeply respect the work behind it, but also because it does something rarely done when validating risk scores: randomization. Usually, we see validation based on

Congrats @katerinadangas on leading this important study evaluating limb outcomes between Medicare FFS and Medicare Advantage patients! @SmithBIDMC @BidmcCvi @rwyeh @rkwadhera @JMKimMD @AndrewOseran

Congratulations @HHLeeMD for your amazing work profiling the total burden of cardiovascular comorbidities among hypertensive patients at AHA Hypertesnion!! @SmithBIDMC @BidmcCvi

Fantastic presentation by @HHLeeMD on trends in prevalence, treatment, and ctrl of risk factors in hypertension #Hypertension2025 @AHAScience @CouncilonHTN @SmithBIDMC @BIDMChealth

We are pleased to announce that Nobel Laureate Professor Josh Angrist will spend a sabbatical year at @SmithBIDMC. Please join us in welcoming Professor Angrist!

The #POTCAST Trial : Potassium optimization improved arrhythmia outcomes, safe in high-risk pts ⚡ POTCAST Trial (Denmark, n=1,200, high VT/ICD risk, K⁺ ≤4.3 mmol/L) 📌Intervention: K⁺ uptitration (target 4.5–5.0) vs std care 📌↑ K⁺ to 4.36 vs 4.05 mmol/L 📌Primary

The Smith Center Renal Denervation Registry is active and open to interested sites! Join 10+ sites across the U.S. and @ACCinTouch on this important hypertension research effort. Learn more about the registry how to participate here: https://t.co/wwebcPHTs7

Thread: Major Changes in 2025 ACC/AHA #Hypertension Guidelines vs 2017 1⃣ BP Classification No change. HTN still defined as ≥130/80 mmHg. Normal <120/80, Elevated 120–129/<80, Stage 1: 130–139/80–89, Stage 2: ≥140/90

@drahmedmohsen85 @aleidimed Here’s the ultra-concise cheat-sheet on today’s AHA/ACC High Blood Pressure Guideline (2025)—what actually changed vs 2017, and how to act on it in clinic. Scope & status Replaces 2017 ACC/AHA; definitions unchanged (Normal <120/80; Elevated 120–129/<80; Stage 1 130–139 or

Measuring success in renal denervation procedures just published in AJC. Free access to manuscript here: @EricSecemskyMD https://t.co/OAI6mIbYXn

[1/10] At last, @MassGenBrigham x @MountSinaiNYC x @PennMedicine x @VUMChealth collaboration on external validation of the @AHAScience's PREVENT is now out in @JACCJournals! https://t.co/VlPkixu2tP

An absolute risk generalizable risk calculator is challenging. Led by @somijemmacho, evaluating AHA PREVENT across 4 academic health systems, we found similar discrimination but variable calibration. A universal absolute risk threshold may not suitably guide.

Renal denervation for HTN was approved the FDA over 18 months ago. But very few cases performed in the US despite a theoretical eligible population >100M patients for this therapy. We cover the elephant in the room: reimbursement in @cardiacinterv. https://t.co/5OdKP7YEe6